Skip to main content
SpringerLink
Log in

Implementation of GLP-1 Based Therapy of Type 2 Diabetes Mellitus Using DPP-IV Inhibitors

  • Chapter
Dipeptidyl Aminopeptidases in Health and Disease

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 524))

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bell, G.I., Sanchez-Pescador, R., Laybourn, P.J., Najarian, R.C., 1983, Exon duplication and divergence in the human preproglucagon gene. Nature, 304(5924):368–371.

    Article  PubMed  CAS  Google Scholar 

  2. Mojsov, S., Heinrich, G., Wilson, I.B., Ravazzola, M., Orci, L., Habener, J.F., 1986, Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing. J Biol Chem, 261(25):11880–11889.

    PubMed  CAS  Google Scholar 

  3. Orskov, C., Hoist, J.J., Knuhtsen, S., Baldissera, F.G., Poulsen, S.S., Nielsen, O.V., 1986, Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas. Endocrinology, 119(4):1467–1475.

    PubMed  CAS  Google Scholar 

  4. Drucker, D.J., Erlich, P., Asa, S.L., Brubaker, P.L., 1996, Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad Sci U S A, 93(15):7911–7916.

    Article  PubMed  CAS  Google Scholar 

  5. Hartmann, B., Thulesen, J., Hare, K.J., Kissow, H., Orskov, C., Poulsen, S.S., et al., 2002, Immunoneutralization of endogenous glucagon-like peptide-2 reduces adaptive intestinal growth in diabetic rats. Regul Pept, 105(3):173–179.

    Article  PubMed  CAS  Google Scholar 

  6. Holst, J.J., 1999, Glucagon-like Peptide l(GLP-l): an intestinal hormone signalling nutritional abundance, with an unusual therapeutic potential. Trends Endocrinol Metab, 10(6):229–234.

    Article  PubMed  CAS  Google Scholar 

  7. Orskov, C., Wettergren, A., Hoist, J.J., 1996, Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day. Scand J Gastroenterol, 31(7):665–670.

    Article  PubMed  CAS  Google Scholar 

  8. Miholic, J., Orskov, C., Holst, J.J., Kotzerke, J., Meyer, H.J., 1991, Emptying of the gastric substitute, glucagon-like peptide-1 (GLP-1), and reactive hypoglycemia after total gastrectomy. Dig Dis Sci, 36(10):1361–1370.

    Article  Google Scholar 

  9. Toft-Nielsen, M., Madsbad, S., Holst, J.J., 1998, Exaggerated secretion of glucagon-like peptide-1 (GLP-1) could cause reactive hypoglycaemia. Diabetologia, 41(10):1180–1186.

    Article  PubMed  CAS  Google Scholar 

  10. Toft-Nielsen, M., Madsbad, S., Holst, J.J., 1996, The effect of glucagon-like peptide I (GLP-I) on glucose elimination in healthy subjects depends on the pancreatic glucoregulatory hormones. Diabetes, 45(5):552–556

    Article  CAS  Google Scholar 

  11. Hansen, L., Hartmann, B., Bisgaard, T., Mineo, H., Jørgensen, P.N., Holst, J.J., 2000, Somatostatin restrains the secretion of glucagon-like peptide-1 and 2 from isolated perfused porcine ileum. Am J Physiol, 278(6):E1010–E1018.

    CAS  Google Scholar 

  12. Fehmann, H.C., Goke, R., Goke, B., 1995, Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide. Endocr Rev, 16(3):390–410.

    Article  PubMed  CAS  Google Scholar 

  13. Weir, G.C., Mojsov, S., Hendrick, G.K., Habener, J.F., 1989, Glucagonlike peptide I (7–37) actions on endocrine pancreas. Diabetes, 38(3):338–342.

    Article  PubMed  CAS  Google Scholar 

  14. Thorens, B., 1992, Expression cloning of the pancreatic beta cell receptor for the glucoincretin hormone glucagon-like peptide 1. Proc Natl Acad Sci U S A, 89(18):8641–8645.

    Article  PubMed  CAS  Google Scholar 

  15. Thorens, B., Porret, A., Buhler, L., Deng, S.P., Morel, P., Widmann, C., 1993, Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9–39) an antagonist of the receptor. Diabetes, 42(11):1678–1682.

    Article  PubMed  CAS  Google Scholar 

  16. Fehmann, H.C., Goke, R., Goke, B., 1995, Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide. Endocr Rev, 16(3):390–410.

    Article  PubMed  CAS  Google Scholar 

  17. Gromada, J., Holst, J. J., Rorsman, P., 1998, Cellular regulation of islet hormone secretion by the incretin hormone glucagon-like peptide 1. Pflugers Arch, 435(5):583–594.

    Article  PubMed  CAS  Google Scholar 

  18. Holz, G.G., Kuhtreiber, W.M., Habener, J.F., 1993, Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-l(7–37). Nature, 361(6410):362–365.

    Article  PubMed  CAS  Google Scholar 

  19. Gromada, J., Dissing, S., Bokvist, K., Renstrom, E., Frokjaer Jensen, J., Wulff, B.S., et al., 1995, Glucagon-like peptide I increases cytoplasmic calcium in insulin-secreting beta TC3-cells by enhancement of intracellular calcium mobilization. Diabetes, 44(7):767–774.

    Article  PubMed  CAS  Google Scholar 

  20. Qualmann, C., Nauck, M.A., Hoist, J.J., Orskov, C., Creutzfeldt, W., 1995, Insulinotropic actions of intravenous glucagon-like peptide-1 (GLP-1) [7–36 amide] in the fasting state in healthy subjects. Ada Diabetol, 32(1):13–16.

    Article  CAS  Google Scholar 

  21. Fehmann, H.C., Habener, J.F., 1992, Insulinotropic hormone glucagon-like peptide-I(7–37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells. Endocrinology, 130(1):159–166.

    Article  PubMed  CAS  Google Scholar 

  22. Buteau, J., Roduit, R., Susini, S., Prentki, M., 1999, Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-l)-cells. Diabetologia, 42(7):856–864.

    Article  PubMed  CAS  Google Scholar 

  23. Xu, G., Staffers, D.A., Habener, J.F., Bonner-Weir, S., 1999, Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes, 48(12):2270–2276.

    Article  PubMed  CAS  Google Scholar 

  24. Stoffers, D.A., Kieffer, T.J., Hussain, M.A., Drucker, D.J., Bonner-Weir, S., Habener, J.F., et al., 2000, Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes, 49(5):741–748.

    Article  PubMed  CAS  Google Scholar 

  25. Zhou, J., Wang, X., Pineyro, M.A., Egan, J.M., 1999, Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon-and insulin-producing cells. Diabetes, 48(12):2358–2366.

    Article  PubMed  CAS  Google Scholar 

  26. Perfetti, R., Zhou, J., Doyle, M.E., Egan, J.M., 2000, Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology, 141(12):4600–4605.

    Article  PubMed  CAS  Google Scholar 

  27. Bregenholt, S., Moldrup, A., Blume, N., Knudsen, L.B., Petersen, J.S., 2001, The GLP-1 analogue, NN2211, inhibits free fatty acid induced apoptosis in primary rat beta cells. Diabetologia, 44[suppl. 1]:A19.

    Google Scholar 

  28. Bregenholt, S., Moldrup, A., Knudsen, L.B., Petersen, J.S., 2001, The GLP-1 derivative NN2211 inhibits cytokine-induced apoptosis in primary rat beta cells. Diabetes, 50[suppl.2]:A31.

    Google Scholar 

  29. Bonner-Weir, S., 2000, Life and death of the pancreatic beta cells. Trends Endocrinol Metab, 11(9):375–378.

    Article  PubMed  CAS  Google Scholar 

  30. Sturis, J., Jappe, M.B., Knudsen, L.B., Wilken, M., Gjedsted, A., Primdahl, S., et al., 2000, Long-acting GLP-1 derivative NN2211 markedly attenuates diabetes development in the male Zucker fatty rat. Diabetologia, 43[supp1.1]:A145.

    Google Scholar 

  31. Pick, A., Clark, J., Kubstrup, C., Levisetti, M., Pugh, W., Bonner-Weir, S., et al., 1998, Role of apoptosis in failure of beta-cell mass compensation for insulin resistance and beta-cell defects in the male Zucker diabetic fatty rat. Diabetes, 47(3):358–364.

    Article  PubMed  CAS  Google Scholar 

  32. Orskov, C., Holst, J.J., Nielsen, O.V., 1988, Effect of truncated glucagon-like peptide-1 [proglucagon-(78–107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. Endocrinology, 123(4):2009–2013.

    Article  PubMed  CAS  Google Scholar 

  33. Orskov, C., Poulsen, S.S., 1991, Glucagonlike peptide-I-(7–36)-amide receptors only in islets of Langerhans. Autoradiographic survey of extracerebral tissues in rats. Diabetes, 40(10):1292–1296.

    Article  PubMed  CAS  Google Scholar 

  34. Heller, R.S., Kieffer, T.J., Habener, J.F., 1997, Insulinotropic glucagon-like peptide I receptor expression in glucagon-producing alpha-cells of the rat endocrine pancreas. Diabetes, 46(5):785–791.

    Article  PubMed  CAS  Google Scholar 

  35. Nauck, M.A., Heimesaat, M.M., Behle, K., Holst, J.J., Nauck, M.S., Ritzel, R., et al., 2002, Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab, 87(3):1239–1246.

    Article  PubMed  CAS  Google Scholar 

  36. Creutzfeldt, W.O., Kleine, N., Willms, B., Orskov, C., Holst, J.J., Nauck, M.A., 1996, Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7–36) amide in type I diabetic patients. Diabetes Care, 19(6):580–586.

    Article  PubMed  CAS  Google Scholar 

  37. Hvidberg, A., Nielsen, M.T., Hilsted, J., Orskov, C., Holst, J.J., 1994, Effect of glucagon-like peptide-1 (proglucagon 78–107-amide) on hepatic glucose production in healthy man. Metabolism, 43(1):104–108.

    Article  PubMed  CAS  Google Scholar 

  38. Wettergren, A., Schjoldager, B., Mortensen, P.E., Myhre, J., Christiansen, J., Holst, J.J., 1993, Truncated GLP-1 (proglucagon 78–107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci, 38(4):665–673.

    Article  PubMed  CAS  Google Scholar 

  39. Nauck, M.A., Niedereichholz, U., Ettler, R., Holst, J.J., Orskov, C., Ritzel, R., et al, 1997, Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol, 273(5 Pt 1):E981–E988.

    PubMed  CAS  Google Scholar 

  40. Holst, J.J., 1997, Enteroglucagon. Annu Rev Physiol, 59:257–71:257–271.

    Article  PubMed  CAS  Google Scholar 

  41. Layer, P., Holst, J.J., Grandt, D., Goebell, H., 1995, Ileal release of glucagon-like peptide-1 (GLP-1). Association with inhibition of gastric acid secretion in humans. Dig Dis Sci, 40(5):1074–1082.

    Article  PubMed  CAS  Google Scholar 

  42. Wettergren, A., Schjoldager, B., Mortensen, P.E., Myhre, J., Christiansen, J., Holst, J.J., 1993, Truncated GLP-1 (proglucagon 78–107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci, 38(4):665–673.

    Article  PubMed  CAS  Google Scholar 

  43. Layer, P., Holst, J.J., Grandt, D., Goebell, H., 1995, Ileal release of glucagon-like peptide-1 (GLP-1). Association with inhibition of gastric acid secretion in humans. Dig DisSci-, 40(5):1074–1082.

    Article  CAS  Google Scholar 

  44. Young, A., Denaro, M., 1998, Roles of amylin in diabetes and in regulation of nutrient load. Nutrition, 14(6):524–527.

    Article  PubMed  CAS  Google Scholar 

  45. Read, N., French, S., Cunningham, K., 1994, The Role of the Gut in Regulation Food Intake in Man. Nutrition Reviews, 52(1):1–10.

    PubMed  CAS  Google Scholar 

  46. Flint, A., Raben, A., Astrup, A., Holst, J.J., 1998, Glucagon-like Peptide 1 Promotes Satiety and Suppresses Energy Intake in Humans. J Clin Invest, 101(3):515–520.

    Article  PubMed  CAS  Google Scholar 

  47. Gutzwiller, J.P., Goke, B., Drewe, J., Hildebrand, P., Ketterer, S., Handschin, D., et al., 1999, Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut, 44(1):81–86.

    Article  PubMed  CAS  Google Scholar 

  48. Naslund, E., Barkeling, B., King, N., Gutniak, M., Blundell, J.E., Holst, J.J., et al., Energy intake and appetite is supressed by glucagon-like peptide-1 (GLP-1) in obese men. Int J Obes. In press.

    Google Scholar 

  49. Gutzwiller, J.P., Drewe, J., Goke, B., Schmidt, H., Rohrer, B., Lareida, J., et al., 1999, Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol, 276(5 Pt 2):R1541–R1544.

    PubMed  CAS  Google Scholar 

  50. Verdich, C., Flint, A., Gutzwiller, J.P., Naslund, E., Beglinger, C., Hellstrom, P.M., et al., 2001, A meta-analysis of the effect of glucagon-like peptide-1 (7–36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab, 86(9):4382–4389.

    Article  PubMed  CAS  Google Scholar 

  51. Turton, M.D., O’Shea, D., Gunn, I., Beak, S.A., Edwards, C.M., Meeran, K., et al., 1996, A role for glucagon-like peptide-1 in the central regulation of feeding [see comments]. Nature, 379(6560):69–72.

    Article  PubMed  CAS  Google Scholar 

  52. Tang-Christensen, M., Larsen, P.J., Goke, R., Fink-Jensen, A., Jessop, D.S., Moller, M., et al., 1996, Central administration of GLP-1-(7–36) amide inhibits food and water intake in rats. Am J Physiol, 271(4 Pt 2):R848–R856.

    PubMed  CAS  Google Scholar 

  53. Goke, R., Larsen, P.J., Mikkelsen, J.D., Sheikh, S.P., 1995, Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites. Eur J Neurosci, 7(11):2294–2300.

    Article  PubMed  CAS  Google Scholar 

  54. Tang-Christensen, M., Vrang, N., Larsen, P.J., 1998, Glucagon-like peptide 1(7–36) amide—s central inhibition of feeding and peripheral inhibition of drinking are abolished by neonatal monosodium glutamate treatment. Diabetes, 47(4):530–537.

    Article  PubMed  CAS  Google Scholar 

  55. Larsen, P.J., Tang-Christensen, M., Holst, J.J., Orskov, C., 1997, Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem. Neuroscience, 77(1):257–270.

    Article  PubMed  CAS  Google Scholar 

  56. Rinaman, L., 1999, Interoceptive stress activates glucagon-like peptide-1 neurons that project to the hypothalamus. Am J Physiol, 277(2 Pt 2):R582–R590.

    PubMed  CAS  Google Scholar 

  57. Rinaman, L., 1999, A functional role for central glucagon-like peptide-1 receptors in lithium chloride-induced anorexia. Am J Physiol, 277(5 Pt 2):R1537–R1540.

    PubMed  CAS  Google Scholar 

  58. Scrocchi, L.A., Brown, T.J., MaClusky, N., Brubaker, P.L., Auerbach, A.B., Joyner, A.L., et al., 1996, Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat Med, 2(11):1254–1258.

    Article  PubMed  CAS  Google Scholar 

  59. Nauck, M.A., Kleine, N., Orskov, C., Holst, J.J., Willms, B., Creutzfeldt, W., 1993, Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7–36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia, 36(8):741–744.

    Article  PubMed  CAS  Google Scholar 

  60. Zander, M., Madsbad, S., Madsen, J.L., Holst, J.J., 2002, Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet, 359(9309):824–830.

    Article  PubMed  CAS  Google Scholar 

  61. Nauck, M.A., Wollschlager, D., Werner, J., Holst, J.J., Orskov, C., Creutzfeldt, W., et al., 1996, Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7–36 amide]) in patients with NIDDM. Diabetologia, 39(12):1546–1553.

    Article  PubMed  CAS  Google Scholar 

  62. Deacon, C.F., Nauck, M.A., Toft-Nielsen, M., Pridal, L., Willms, B, Holst, J.J, 1995, Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes, 44(9):1126–1131.

    Article  PubMed  CAS  Google Scholar 

  63. Deacon, C.F., Johnsen, A.H., Holst, J.J., 1995, Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab, 80(3):952–957.

    Article  PubMed  CAS  Google Scholar 

  64. Knudsen, L.B., Pridal, L., 1996, Glucagon-like peptide-1-(9–36) amide is a major metabolite of glucagon-like peptide-1-(7–36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor. Eur J Pharmacol, 318(2–3):429–435.

    Article  PubMed  CAS  Google Scholar 

  65. Hansen, L., Deacon, C.F., Orskov, C., Holst, J.J., 1999, Glucagon-like peptide-1-(7–36)amide is transformed to glucagon-like peptide-1-(9–36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology, 140(11):5356–5363.

    Article  PubMed  CAS  Google Scholar 

  66. Wettergren, A., Wojdemann, M., Holst, J.J., 1998, Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow. Am J Physiol, 275(5 Pt 1):G984–G992.

    PubMed  CAS  Google Scholar 

  67. Imeryuz, N., Yegen, B.C., Bozkurt, A., Coskun, T., Villanueva-Penacarrillo, M.L., Ulusoy, N.B., 1997, Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. Am J Physiol, 273(4 Pt 1):G920–G927.

    PubMed  CAS  Google Scholar 

  68. Nakabayashi, H., Nishizawa, M., Nakagawa, A., Takeda, R., Niijima, A., 1996, Vagal hepatopancreatic reflex effect evoked by intraportal appearance of tGLP-1. Am J Physiol, 271(5 Pt 1):E808–E813.

    PubMed  CAS  Google Scholar 

  69. Balkan, B., Li, X., 2000, Portal GLP-1 administration in rats augments the insulin response to glucose via neuronal mechanisms. Am J Physiol Regul Integr Comp Physiol, 279(4):R1449–R1454.

    PubMed  CAS  Google Scholar 

  70. Wettergren, A., Wojdemann, M., Meisner, S., Stadil, F., Holst, J.J., 1997, The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7–36 amide on gastric acid secretion in humans depends on an intact vagal innervation. Gut, 40(5):597–601.

    PubMed  CAS  Google Scholar 

  71. Wettergren, A., Petersen, H., Orskov, C., Christiansen, J., Sheikh, S.P., Holst, J.J., 1994, Glucagon-like peptide-1 7–36 amide and peptide YY from the L-cell of the ileal mucosa are potent inhibitors of vagally induced gastric acid secretion in man. Scand J Gastroenterol, 29(6):501–505.

    Article  PubMed  CAS  Google Scholar 

  72. Vilsboll, T., Krarup, T., Deacon, C.F., Madsbad, S., Holst, J.J., 2001, Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes, 50(3):609–613.

    Article  PubMed  CAS  Google Scholar 

  73. Holst, J.J., Deacon, C.F., 1998, Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Diabetes, 47(11):1663–1670.

    Article  PubMed  CAS  Google Scholar 

  74. Deacon, C.F., Pridal, L., Klarskov, L., Olesen, M., Holst, J.J., 1996, Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. Am J Physiol, 271(3 Pt 1):E458–E464.

    PubMed  CAS  Google Scholar 

  75. Vilsboll, T., Agersoe, H., Krarup, T., Holst, J.J., Similar elimination rates of GLP-1 in obese type diabetic patients and healthy subjects. J Clin Endocrinol Metab., in press.

    Google Scholar 

  76. Deacon, C.F., Hughes, T.E., Holst, J.J., 1998, Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig. Diabetes, 47(5):764–769.

    Article  PubMed  CAS  Google Scholar 

  77. Ahren, B., Holst, J.J., Martensson, H., Balkan, B., 2000, Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice. Eur J Pharmacol, 404(1–2):239–245.

    Article  PubMed  CAS  Google Scholar 

  78. Pospisilik, J.A., Stafford, S.G., Demuth, H.U., Brownsey, R., Parkhouse, W., Finegood, D.T., et al, 2002, Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats. Diabetes, 51(4):943–950.

    Article  PubMed  CAS  Google Scholar 

  79. Ahren, B., Simonsson, E., Larsson, H., Landin-Olsson, M., Torgeirsson, H., Jansson, P.A., et al., 2002, Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care, 25(5):869–875.

    Article  PubMed  CAS  Google Scholar 

  80. Mentlein, R., 1999, Dipeptidyl-peptidase IV (CD26)—role in the inactivation of regulatory peptides. Regul Pept, 85(1):9–24.

    Article  PubMed  CAS  Google Scholar 

  81. Pederson, R.A., Kieffer, T.J., Pauly, R., Kofod, H., Kwong, J., McIntosh, C.H., 1996, The enteroinsular axis in dipeptidyl peptidase IV-negative rats. Metabolism, 45(11):1335–1341.

    Article  PubMed  CAS  Google Scholar 

  82. Marguet, D., Baggio, L., Kobayashi, T., Bernard, A.M., Pierres, M., Nielsen, P.F., et al., 2000, Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc Natl Acad Sci U S A, 97(12):6874–6879.

    Article  PubMed  CAS  Google Scholar 

  83. Deacon, C.F., Wamberg, S., Bie, P., Hughes, T.E., Holst, J.J., 2002, Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs. J Endocrinol, 172(2):355–362.

    Article  PubMed  CAS  Google Scholar 

  84. Li, X., Kwasnik, L., Miserendino, R., Mone, M., Hughes, T.E., Vilhauer, E.B., et al., 1997, Improved insulin secretion and oral glucose tolerance after in vivo inhibition of DPP-IV in insulin resistant rats. Diabetes, 46[suppl.1]: 237A.

    Google Scholar 

  85. Sudre, B., Broqua, P., White, R.B., Ashworth, D., Evans, D.M., Haigh, R., et al., 2002, Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male zucker diabetic fatty rats. Diabetes, 51(5):1461–1469.

    Article  PubMed  CAS  Google Scholar 

  86. Ritzel, R., Orskov, C., Holst, J.J., Nauck, M.A., 1995, Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7–36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships. Diabetologia, 38(6):720–725.

    Article  PubMed  CAS  Google Scholar 

  87. Rachman, J., Barrow, B.A., Levy, J.C., Turner, R.C., 1997, Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM. Diabetologia, 40(2):205–211.

    Article  PubMed  CAS  Google Scholar 

  88. Larsen, J., Hylleberg, B., Ng, K., Damsbo, P., 2001, Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment. Diabetes Care, 24(8):1416–1421.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Physiology, University of Copenhagen, The Panum Institute, DK-2200, Copenhagen N.

    Jens Juul Holst

Authors
  1. Jens Juul Holst
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University of Milan, Italy

    Rodolfo Paoletti

  2. State University of New York at Buffalo, USA

    Nathan Back

  3. The Weizmann Institute of Science, Israel

    Irun R. Cohen

  4. Wistar Institute, USA

    David Kritchevsky

  5. N.S. Kline Institute for Psychiatric Research, USA

    Abel Lajtha

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Kluwer Academic Publishers

About this chapter

Cite this chapter

Holst, J.J. (2004). Implementation of GLP-1 Based Therapy of Type 2 Diabetes Mellitus Using DPP-IV Inhibitors. In: Back, N., Cohen, I.R., Kritchevsky, D., Lajtha, A., Paoletti, R. (eds) Dipeptidyl Aminopeptidases in Health and Disease. Advances in Experimental Medicine and Biology, vol 524. Springer, Boston, MA. https://doi.org/10.1007/0-306-47920-6_33

Download citation

  • DOI: https://doi.org/10.1007/0-306-47920-6_33

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-306-47717-1

  • Online ISBN: 978-0-306-47920-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation